- Home
- BGM vs NEO Comparison
BGM vs NEO Comparison
Compare BGM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGM
- NEO
- Stock Information
- Founded
- BGM 2019
- NEO 2001
- Country
- BGM China
- NEO United States
- Employees
- BGM N/A
- NEO N/A
- Industry
- BGM
- NEO Precision Instruments
- Sector
- BGM
- NEO Health Care
- Exchange
- BGM NYSE
- NEO Nasdaq
- Market Cap
- BGM 1.0B
- NEO 1.2B
- IPO Year
- BGM 2021
- NEO 1999
- Fundamental
- Price
- BGM $11.00
- NEO $9.55
- Analyst Decision
- BGM
- NEO Strong Buy
- Analyst Count
- BGM 0
- NEO 10
- Target Price
- BGM N/A
- NEO $19.44
- AVG Volume (30 Days)
- BGM 38.0K
- NEO 1.9M
- Earning Date
- BGM 04-29-2025
- NEO 04-29-2025
- Dividend Yield
- BGM N/A
- NEO N/A
- EPS Growth
- BGM N/A
- NEO N/A
- EPS
- BGM N/A
- NEO N/A
- Revenue
- BGM $25,097,951.00
- NEO $660,566,000.00
- Revenue This Year
- BGM N/A
- NEO $13.06
- Revenue Next Year
- BGM N/A
- NEO $11.18
- P/E Ratio
- BGM N/A
- NEO N/A
- Revenue Growth
- BGM N/A
- NEO 11.65
- 52 Week Low
- BGM $2.70
- NEO $8.05
- 52 Week High
- BGM $14.78
- NEO $19.11
- Technical
- Relative Strength Index (RSI)
- BGM 54.14
- NEO 48.48
- Support Level
- BGM $9.35
- NEO $8.05
- Resistance Level
- BGM $11.84
- NEO $10.18
- Average True Range (ATR)
- BGM 0.71
- NEO 0.72
- MACD
- BGM -0.01
- NEO 0.16
- Stochastic Oscillator
- BGM 66.43
- NEO 70.42
About BGM QILIAN INTERNATIONAL HLDG GROUP LTD
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.